Antibe Therapeutics Inc
TSX:ATE

Watchlist Manager
Antibe Therapeutics Inc Logo
Antibe Therapeutics Inc
TSX:ATE
Watchlist
Price: 0.295 CAD Market Closed
Market Cap: 4.7m CAD

Relative Value

There is not enough data to reliably calculate the relative value of ATE.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ATE Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
-0.3
Median 5Y
-0.4
Industry
21.7
Forward
-0.2
vs History
vs Industry
Median 3Y
-0.3
Median 5Y
-0.5
Industry
16.7
vs History
vs Industry
Median 3Y
-0.3
Median 5Y
-0.5
Industry
23.1
vs History
vs Industry
Median 3Y
0.2
Median 5Y
0.2
Industry
2.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
1.2
Median 5Y
1.2
Industry
13.2
Forward
1
vs History
vs Industry
Median 3Y
1.2
Median 5Y
1.2
Industry
16.8
Forward
1
vs History
vs Industry
Median 3Y
1.3
Median 5Y
1.3
Industry
15.9
vs History
vs Industry
Median 3Y
1.3
Median 5Y
1.3
Industry
19.2
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-0.8
Industry
1.9

Multiples Across Competitors

ATE Competitors Multiples
Antibe Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Antibe Therapeutics Inc
TSX:ATE
4.7m CAD 0 -0.3 1.2 1.2
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.1 36.9 39.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
495.1B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
262.5B CHF 4.3 27.8 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
213B GBP 4.9 30.6 108.9 159.4
CH
Novartis AG
SIX:NOVN
211.3B CHF 4.8 18.6 11.8 15.2
US
Merck & Co Inc
NYSE:MRK
261.3B USD 4.1 13.7 9.8 11.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.7 14.2 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
141.5B USD 2.3 14.4 7.4 10.1
P/E Multiple
Earnings Growth PEG
CA
Antibe Therapeutics Inc
TSX:ATE
Average P/E: 24.3
Negative Multiple: -0.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.1
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.6
38%
0.8
CH
Novartis AG
SIX:NOVN
18.6
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.7
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
4%
3.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.4
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Antibe Therapeutics Inc
TSX:ATE
Average EV/EBITDA: 399.2
1.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
4%
3
UK
AstraZeneca PLC
LSE:AZN
108.9
10%
10.9
CH
Novartis AG
SIX:NOVN
11.8
6%
2
US
Merck & Co Inc
NYSE:MRK
9.8
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
2%
5
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Antibe Therapeutics Inc
TSX:ATE
Average EV/EBIT: 1 710.5
1.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.6
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
159.4
23%
6.9
CH
Novartis AG
SIX:NOVN
15.2
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.6
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
1%
11.5
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3